Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Exact Sciences (NASDAQ: EXAS) is one of the companies capitalizing on those opportunities. Its Cologuard test screens for colorectal cancer and has helped the company generate significant sales growth along the way. The business is promising and the company also has other tests which help screen for breast cancer and liver cancer.
Cathie Wood of ARK Invest says AI will trigger an "astounding and shocking" surge in productivity.